Filipinler - İngilizce - FDA (Food And Drug Administration)

n/a; importer: sanofi pasteur, inc.; distributor: sanofi pasteur, inc. - quadrivalent seasonal influenza vaccine (split virion, inactivated) 2023 southern hemisphere strain - suspension for injection (im) - formulation: each dose (0.5 ml) contains: a/victoria/2570/2019 ivr-215(hini)-15 mcg* a/darwin/9/2021 san-010 (h3n2)-15 mcg*

Suudi Arabistan - İngilizce - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

sanofi pasteur, france - influenza a virus a/indonesia/5/2005 (h5n1) antigen (uv, formaldehyde inactivated) - suspension for injection in pre-filled syringe - 15 µg,

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - codeine phosphate hemihydrate,doxylamine succinate,paracetamol -

Singapur - İngilizce - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - cyd dengue virus serotype 1; cyd dengue virus serotype 2; cyd dengue virus serotype 3; cyd dengue virus serotype 4 - injection, powder, for suspension - cyd dengue virus serotype 1 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 2 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 3 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 4 4.5 - 6.0 log10 ccid50/dose

Singapur - İngilizce - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - bacillus calmette-guerin - injection, powder, lyophilized, for solution - 81mg/vial

Singapur - İngilizce - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - cyd dengue virus serotype 1; cyd dengue virus serotype 2; cyd dengue virus serotype 3; cyd dengue virus serotype 4 - injection, powder, for suspension - cyd dengue virus serotype 1 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 2 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 3 4.5 - 6.0 log10 ccid50/dose; cyd dengue virus serotype 4 4.5 - 6.0 log10 ccid50/dose

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diphtheria toxoid, quantity: 48 microgram; meningococcal polysaccharide group y, quantity: 4 microgram; meningococcal polysaccharide group w135, quantity: 4 microgram; meningococcal polysaccharide group c, quantity: 4 microgram; meningococcal polysaccharide group a, quantity: 4 microgram - injection, solution - excipient ingredients: monobasic sodium phosphate; sodium chloride; dibasic sodium phosphate - menactra is indicated for active immunisation of individuals 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by n meningitidis serogroups a, c, y and w-135.,menactra is not indicated for the prevention of meningitis caused by other microorganisms or for the prevention of invasive meningococcal disease caused by n meningitidis serogroup b.,menactra is not indicated for treatment of meningococcal infections.,menactra is not indicated for immunisation against diphtheria.

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

sanofi pasteur - a/michigan/45/2015 (h1n1)pdm09 - like strain (a/michigan/45/2015, nymc x-275); a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b); b/brisbane/60/2008 - like strain (b/brisbane/60/2008) - suspension for injection - 15/15/15mc percent volume/volume - influenza vaccines; influenza, inactivated, split virus or surface antigen

Uganda - İngilizce - National Drug Authority

sanofi pasteur - yellow fever virus 17d-204 strain(live attenuated) - parenteral ordinary vials - nlt 1000 i.u

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - risedronate sodium; calcium carbonate; colecalciferol; cholecalciferol -